What Is Gene Sight Testing? Pros, Cons, and More

Gene sight testing is one of the best-known pharmacogenomic tests for psychiatric medications. This guide explains what the test looks at, how to read its report, how it compares with other PGx testing approaches, and the questions worth asking before you and your prescriber choose any test.

Pharmacogenomic testing, also known as PGx testing, gives insights into your genetic makeup. In case of certain medications, this information is utilised to tailor treatments that have the least chance of trial and error. GeneSight testing is a branch of pharmacogenomic testing that assists healthcare providers in tailoring psychiatric treatments, such as depression, anxiety, ADHD, and bipolar disorder. In this guide, we explore the answer to the question: What is Gene Sight Testing, including its FDA acceptance and clinical applications?

FDA Acceptance and Regulatory Status

GeneSight testing has not been approved as a standalone diagnostic tool by the U.S. Food and Drug Administration (FDA). However, the FDA recognises the potential of pharmacogenomic testing in informing medication selection and dosing when supported by robust scientific evidence. In 2020, the FDA announced a collaborative review of scientific evidence to support associations between genetic information and specific medications, indicating a growing interest in integrating genetic data into clinical decision-making.

Understanding Gene Sight Testing

How It Works

GeneSight testing analyses genetic variations in a panel of genes that influence the metabolism and response to psychiatric medications. The test categorises dozens of psychiatric medications into three groups (check with the company for the current gene and medication list):

• Use as Directed: Medications are expected to work well at standard doses.
• Moderate Gene-Drug Interaction: Medications that may require dose adjustments.
• Significant Gene-Drug Interaction: Medications that may be less effective or cause side effects due to genetic variations.

The test employs a combinatorial algorithm to integrate data from multiple genes, providing a comprehensive overview of how genetic factors may affect medication outcomes.

Benefits of GeneSight Testing

• Personalised Treatment: Assists clinicians in selecting medications that align with a patient’s genetic profile, potentially reducing trial-and-error prescribing.
• Improved Outcomes: Studies have shown that GeneSight-guided treatment can lead to higher remission and response rates in patients with major depressive disorder.
• Safety Considerations: Identifies potential risks, such as increased susceptibility to severe skin reactions like Stevens-Johnson Syndrome when taking certain medications. Limitations
• Not a Diagnostic Tool: GeneSight testing does not diagnose mental health conditions or predict medication efficacy with absolute certainty.
• Genetic Variability: Genetic factors are just one aspect of medication response; other elements like environment and lifestyle also play significant roles.
• Insurance Coverage: Coverage varies among insurance providers, and some plans may not fully reimburse the cost of the test.

FDA-Approved Antidepressants with Pharmacogenomic Evidence

Genetic factors can influence how the body processes many antidepressants. For some, such as citalopram, fluoxetine, paroxetine, amitriptyline, nortriptyline, venlafaxine and vortioxetine, the FDA includes pharmacogenomic information in the drug labelling. For others, the evidence comes from CPIC guidelines (for example sertraline and escitalopram) or from ongoing research. Antidepressants that pharmacogenomic panels commonly report on include:

• Citalopram (Celexa)
• Escitalopram (Lexapro)
• Fluoxetine (Prozac)
• Paroxetine (Paxil)
• Sertraline (Zoloft)
• Amitriptyline (Elavil)
• Nortriptyline (Pamelor)
• Duloxetine (Cymbalta)
• Venlafaxine (Effexor)
• Mirtazapine (Remeron)
• Trazodone (Desyrel)
• Bupropion (Wellbutrin)
• Vortioxetine (Trintellix)

The strength of the pharmacogenomic evidence differs from drug to drug. Some, like duloxetine, mirtazapine, trazodone and bupropion, do not have gene-based dosing guidance in their FDA labelling, so genetic results are one input among many when prescribing.

Book an at-home PGx test from RPh LABS now.

Cost of Genesight With and Without Insurance Coverage

The GeneSight testing cost varies depending on insurance coverage and financial assistance programs:

• Medicare (Part B): Coverage depends on meeting Medicare’s medical necessity criteria; check with the company and Medicare about what you may owe.
• Medicare Advantage (Part C): Coverage may vary; patients might pay a portion of the cost.
• Medicaid: Coverage varies by state; check with your state Medicaid plan.
• Commercial Insurance: Coverage varies; patients may pay a portion of the cost, so check with your insurer before testing.
• Uninsured: Ask the company directly about current self-pay pricing and any financial assistance programs.

History of GeneSight Testing

Gene Sight testing emerged from advancements in pharmacogenomics, the study of how genes affect individual responses to medications. The test is offered by Myriad Genetics and has been utilised by healthcare providers to personalise psychiatric treatment plans. Over time, the test has undergone enhancements to include a broader range of medications and genetic markers, aiming to improve the precision of psychiatric care.

Future Outlook

The field of pharmacogenomics continues to evolve, with ongoing research aimed at expanding the understanding of genetic influences on medication response. Future developments may include:

• Expanded Genetic Markers: Incorporating additional genes to provide a more comprehensive analysis.
• Broader Medication Coverage: Including a wider array of psychiatric medications in testing panels.
• Integration with Electronic Health Records (EHRs): Facilitating seamless incorporation of genetic information into clinical decision-making processes.

As research progresses, pharmacogenomic testing like GeneSight may become an integral component of personalised psychiatric care.

How to read GeneSight test results

GeneSight test results group each listed medication into one of three categories, as described earlier: use as directed, moderate gene-drug interaction, and significant gene-drug interaction. The report is designed so a clinician can scan it quickly.

A few points help when you look at your own report:

• A medication in a moderate or significant category is not banned. It means your genes may affect how that drug is processed or tolerated, so your prescriber may adjust the dose, monitor more closely or consider another option.
• A medication in the use as directed category is not guaranteed to work. The report reflects gene-drug interactions, not whether your symptoms will improve.
• The report reflects your genes, not the other medicines you take. Drug interactions can still change how a medication behaves.

If your report also lists individual gene results, such as your CYP2D6 or CYP2C19 metabolizer status, keep that page. Those gene-level results can be applied to future prescriptions, including medicines that are not on the psychiatric list.

Always review GeneSight test results with the clinician who ordered the test, and do not stop or change a medication on your own.

Combined reports versus gene-by-gene reports

PGx labs present results in different ways, and it helps to know the two main styles.

A combinatorial report, the approach GeneSight uses, weighs several genes together with the lab’s own algorithm and places each drug into a single category. The benefit is a simple, at-a-glance view for each medication.

A gene-by-gene report lists your result for each gene, such as your CYP2D6 metabolizer status, and then links each medication to published guidance from groups like CPIC or to FDA labeling. The benefit is that a clinician or pharmacist can trace exactly which gene drives each recommendation.

Neither style changes your DNA or the underlying science. They are different ways of organizing the same kind of information. Many clinicians are comfortable with both. What matters most is that the report covers the medications you and your prescriber care about, and that someone qualified helps you interpret it.

If you are ever unsure how a category or recommendation was reached, ask the lab or your pharmacist to explain which gene result it is based on.

Genes commonly covered in psychiatric pgx testing

Most psychiatric pgx testing focuses on a core group of genes. The exact list varies by lab and changes over time, so check each provider’s current gene list before you order.

• CYP2D6: many antidepressants, some antipsychotics such as aripiprazole, and ADHD medicines such as atomoxetine.
• CYP2C19: citalopram, escitalopram, sertraline and several tricyclics.
• CYP2B6: sertraline and bupropion metabolism.
• CYP3A4 and CYP2C9: other drugs used in psychiatry and beyond.
• HLA-A and HLA-B: serious skin reaction risk with carbamazepine and related drugs, included on some panels.
• Receptor and transporter genes such as HTR2A and SLC6A4: included by some labs, although current CPIC guidance does not base dosing on them.

The metabolism genes carry most of the published prescribing guidance. You can see which gene-drug pairs have CPIC guidelines at cpicpgx.org. When you compare psychiatric pgx testing options, look for coverage of CYP2D6 and CYP2C19 at a minimum.

What guidelines say about genetic testing for depression medication

Genetic testing for depression medication has a stronger evidence base than many people expect, but it is specific. The clearest guidance links metabolism genes to particular drugs.

• CPIC guidelines cover SSRIs and related antidepressants with CYP2D6, CYP2C19 and CYP2B6, and tricyclic antidepressants with CYP2D6 and CYP2C19.
• The citalopram label limits the maximum daily dose for CYP2C19 poor metabolizers.
• The vortioxetine label sets a lower maximum dose for CYP2D6 poor metabolizers.

You can look up any drug in the FDA table of pharmacogenomic biomarkers in drug labeling. Not every antidepressant appears there, and drugs that are not listed may still have CPIC guidance, so both sources are worth checking.

What guidelines do not do is predict whether a specific antidepressant will relieve your depression. Genetic testing for depression medication helps with dosing and with avoiding known gene-drug problems. Your diagnosis, history, other medicines and therapy options still shape the plan. Our article on genetic testing for antidepressants covers these gene-drug pairs in more depth.

Questions to ask when comparing gene sight testing and other PGx tests

Whether you are considering gene sight testing or another lab, the same questions help you compare fairly:

1. Which genes are tested, and does the list include CYP2D6 and CYP2C19?
2. Which medications does the report cover, and are they only psychiatric drugs or also other areas such as heart health and pain?
3. Is the lab CLIA-certified, and does it hold additional accreditation?
4. Does the test need a clinician order, and can you collect the sample at home?
5. How long do results take after the sample arrives?
6. Is a pharmacist or clinician available to explain the report?
7. Will the report be updated when guidelines change?
8. What will it cost you? Ask the provider and your insurer directly, since coverage and out-of-pocket costs depend on your plan.

Write down the answers side by side. It makes it easier to discuss the options with your prescriber and choose the test that fits your needs.

When a broader panel may be a genesight alternative

Some people want a test focused on psychiatric medications. Others want one result that also covers prescriptions from other specialties. In the second case, a broader PGx panel can be a genesight alternative worth discussing with your prescriber.

Broader panels often include genes with well-known guidance outside mental health, for example:

• CYP2C19 and clopidogrel, where poor metabolizers get less benefit.
• SLCO1B1 and simvastatin, where decreased function raises muscle side effect risk.
• CYP2C9 and VKORC1 with warfarin dosing.
• TPMT and NUDT15 with thiopurines such as azathioprine.
• CYP2D6 with codeine and tramadol, which need the enzyme to become active.

The RPh Labs panel is one example of this approach. It tests 20 genes, reports against 240+ medications, and uses an at-home cheek swab with a PharmD pharmacist review of every report. You can see which drugs are covered on the medication list by gene or read about the at-home kit. Which genesight alternative, if any, suits you depends on the medications you take and what your prescriber needs.

Who might consider psychiatric PGx testing

PGx testing is not a routine step for everyone who starts a psychiatric medication. It tends to be most helpful in specific situations, whichever lab you use:

• You have tried one or more medications at an adequate dose without enough benefit.
• You had strong side effects at a low or standard dose.
• You take several medications, which raises the chance of interactions.
• Your prescriber is considering a drug with gene guidance, such as citalopram, escitalopram, paroxetine, a tricyclic or aripiprazole.
• You want one result that can inform prescriptions for years to come.

It is less likely to change decisions if you are doing well on your current medication with no side effects. Even then, some people test so the information is ready if their treatment changes later.

Testing also has limits worth knowing up front. It does not diagnose depression, anxiety or any other condition. It does not replace a careful history, therapy, or follow-up visits. And results are one input alongside age, kidney and liver function, other medicines and personal preferences.

For a trusted overview of how psychiatric medications are used, see the NIMH mental health medications page. Your prescriber can then help you decide whether testing, and which kind, makes sense for you.

Using any PGx report with your prescriber

Whichever test you choose, the report only helps if it becomes part of your care. A few habits make that more likely.

• Share the full report with your prescriber and pharmacist, not just the summary page.
• Keep an up-to-date medication list. Drugs like fluoxetine, paroxetine and bupropion block CYP2D6 and can make a normal metabolizer act like a poor one, which is called phenoconversion.
• Keep taking your medication as prescribed while you review results. Any change should be planned with your prescriber.
• Store the report somewhere you can find it. Your genes do not change, so the results stay relevant for life.

If you have results from more than one lab, bring both. Labs test different sets of variants, especially for CYP2D6, so small differences are possible. A pharmacist can help reconcile them.

For a plain-language primer on the science behind all of these tests, MedlinePlus explains pharmacogenomics clearly, and our guide to what PGx testing is covers the basics.

Conclusion

Genetic testing for medication is commonly known as pharmacogenomics testing or PGx. GeneSight is a pharmacogenomic test that focuses on how a patient’s genes may affect their response to psychiatric medications. The answer to ‘how accurate is genetic testing for psychiatric medications’ depends on which medication you are going to be administered. A PGx test from RPh LABS (CLIA certified) shows how your body may respond to 240+ medications. Unsure about the at-home PGx testing? Here is how it works.

Disclaimer: This blog is only for informational purposes. Please always consult a doctor before taking any medical action.

Gene sight testing FAQ

Do GeneSight test results tell me which antidepressant will work?

No test can promise that. GeneSight test results, like other PGx reports, show how your genes may affect the processing or tolerability of specific drugs. Your prescriber uses that alongside your diagnosis, history, other medicines and preferences to choose a treatment.

Can I use PGx results from one lab with a different prescriber?

Yes. Your genes do not change, so any valid report can be shared with a new prescriber or pharmacist. Keep a copy of the full report, including the individual gene results, so it can be applied to new medications.

Is psychiatric pgx testing useful for medicines outside mental health?

It depends on the genes tested. A CYP2D6 or CYP2C19 result applies to any drug that uses that enzyme, including some pain and heart medicines. Panels focused only on psychiatric drugs may not report on those medications, so ask the lab what is covered.

Should I get tested again if I already had a PGx test?

Usually not for the same genes. If your earlier test did not include genes you now need, such as SLCO1B1 before a statin, your prescriber may consider a test that covers them. Ask your pharmacist to compare what you already have first.

How do I choose between a focused test and a broader panel?

Start with the medicines you take now and are likely to need later. If your questions are only about psychiatric drugs, a focused test may be enough. If you also take heart, pain or other medicines, a broader panel may be more useful. Decide together with your prescriber.